LIMN Utang jangka cendhak perusahaan Liminatus

Liminatus Pharma (LIMN) aims for dominance in the gastrointestinal cancer therapy segment via its GCC CAR-T platform, while the company's short-term liability structure shows a figure at 0.00. A lack of sales and post-SPAC risks create financial instability. The current development vector relies on organic growth and the search for partners among academic institutions to conduct research.

Analyzing the resilience of Liminatus Pharma (LIMN) to external shocks requires liquidity monitoring, particularly given the risks of raw material supply disruptions from Asia and delays in clinical trials. The dynamics of current short-term liabilities reflect the total volume of debt maturing within one year, allowing investors to assess the risk of cash flow gaps and the efficiency of debt capital management to ensure the operational reliability of the business.